|Assessment Status||Rapid Review Complete|
|Drug||Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide|
|Indication||Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide (Trimbow®) is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disorder (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA) or a combination of a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA).|
|Rapid review commissioned||21/06/2023|
|Rapid review completed||19/07/2023|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that Trimbow® for this indication not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.